Synairgen (SNG) Share Price, News & Analysis

Company Overview

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Key Stats

• Today's Range: 4.60 to 4.77
• 50-Day Range: 3.22 to 5.50
• 52-Week Range: 3 to 11
• Volume: 129,781 shs
• Average Volume: 347,950 shs
• Market Capitalization: £9.60 million
• P/E Ratio: N/A
• Dividend Yield: 1.53%
• Price Target: N/A
• Consensus Rating: N/A

SNG Stock Analysis - Frequently Asked Questions

How have SNG shares performed this year?

Synairgen's stock was trading at GBX 5.98 at the start of the year. Since then, SNG shares have decreased by 20.3% and is now trading at GBX 4.77.
View the best growth stocks for 2024 here.

How were Synairgen's earnings last quarter?

Synairgen plc (LON:SNG) posted its quarterly earnings data on Tuesday, September, 29th. The company reported ($3.11) earnings per share for the quarter.

How do I buy shares of Synairgen?

Shares of SNG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Synairgen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synairgen investors own include Lloyds Banking Group (LLOY), AstraZeneca (AZN), Alibaba Group (BABA), boohoo group (BOO), Barclays (BARC), VanEck Gold Miners ETF (GDX) and Legal & General Group (LGEN).

Company Calendar

• Last Earnings: 9/29/2020
• Today: 11/02/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:SNG
• CUSIP: N/A
• CIK: N/A
• Web: www.synairgen.com
• Phone: +44-23-80512800
• Fax: N/A
• Employees: 34
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-42,870,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -48.86%
• Return on Assets: -30.58%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 6.77
• Quick Ratio: 6.35

Sales & Book Value

• Annual Sales: £79,000.00
• Price / Sales: 121.47
• Cash Flow: GBX 2.51 per share
• Price / Cash Flow: 1.90
• Book Value: GBX 26 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 201,380,000
• Free Float: N/A
• Market Cap: £9.60 million
• Optionable: Not Optionable
• Beta: -2.23